Oklo Inc.’s OKLO isotopes business is emerging as a key pillar within its broader nuclear platform, targeting a critical gap in the supply of high-value radioactive materials. These isotopes are essential for applications ranging from cancer treatment and diagnostic imaging to advanced manufacturing and national security, making this segment strategically important. Today, global supply remains fragile, with production concentrated in a few aging reactors outside the United States. As many of these facilities approach retirement, supply risks are rising even as demand accelerates, particularly in nuclear medicine, where millions of procedures depend on timely isotope availability.
To address this imbalance, OKLO is developing an integrated production model that converts nuclear waste into valuable isotopes. By sourcing material through both domestic and international waste partnerships, OKLO is building a system that can receive waste, process it, and deliver usable isotopes efficiently. This approach is designed to strengthen supply reliability while reducing reliance on foreign sources. Early-stage facilities, such as the Idaho Radiochemistry Laboratory, are expected to generate initial output while helping validate production methods and bridge the transition from pilot-scale operations to commercial deployment.
A phased infrastructure rollout underpins this strategy, with multiple facilities planned to scale production over time. The Groves Isotope Test Reactor in Texas is intended to demonstrate reactor performance and validate isotope production pathways before larger commercial facilities are developed. Over time, additional assets such as multi-reactor isotope foundries and fuel recycling centers are expected to expand output and integrate isotope production into the broader nuclear fuel cycle. This layered approach reflects OKLO’s effort to establish a stable, domestic supply chain capable of supporting growing demand across health care, industry and research.
While OKLO is pursuing a vertically integrated approach, it is not the only company positioned to benefit from rising isotope demand. A handful of other players are also building strong positions in this market through established production capabilities, government partnerships and broad distribution networks.